BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DPB, Melmed GY. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:1746-51. [PMID: 34047304 DOI: 10.14309/ajg.0000000000001342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li D, Xu A, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Prostko JC, Frias EC, Stewart JL, Pozdnyakova V, Debbas P, Mujukian A, Horizon AA, Merin N, Joung S, Botwin GJ, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, Braun J. The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders. medRxiv 2021:2021. [PMID: 34909785 DOI: 10.1101/2021.12.08.21267444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Chen L, Cai X, Zhao T, Han B, Xie M, Cui J, Zhang J, Wang C, Liu B, Lu Q, Cui F. Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis. Vaccines 2022;10:596. [DOI: 10.3390/vaccines10040596] [Reference Citation Analysis]
3 Tepasse PR, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life (Basel) 2021;11:1220. [PMID: 34833096 DOI: 10.3390/life11111220] [Reference Citation Analysis]
4 Orfanoudaki E, Zacharopoulou E, Kitsou V, Karmiris K, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Viazis N, Liatsos C, Bamias G, Koutroubakis IE, On Behalf Of The Hellenic Group For The Study Of Ibd. Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. J Clin Med 2022;11:641. [PMID: 35160092 DOI: 10.3390/jcm11030641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Briggs FBS, Mateen FJ, Schmidt H, Currie KM, Siefers HM, Crouthamel S, Bebo BF, Fiol J, Racke MK, O'Connor KC, Kolaczkowski LG, Klein P, Loud S, McBurney RN. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm 2022;9:e1104. [PMID: 34753828 DOI: 10.1212/NXI.0000000000001104] [Reference Citation Analysis]
6 Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines 2022;10:759. [DOI: 10.3390/vaccines10050759] [Reference Citation Analysis]
7 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
8 Cannatelli R, Ferretti F, Carmagnola S, Bergna IMB, Monico MC, Maconi G, Ardizzone S. Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut 2021:gutjnl-2021-326237. [PMID: 34819330 DOI: 10.1136/gutjnl-2021-326237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 Hudhud D, Caldera F, Cross RK. Addressing COVID-19 Vaccine Hesitancy in Patients with IBD. Inflamm Bowel Dis 2021:izab241. [PMID: 34559239 DOI: 10.1093/ibd/izab241] [Reference Citation Analysis]
10 Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Boccieri ME, Firestine A, Kappelman MD, Long MD. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis 2021:izab302. [PMID: 34871388 DOI: 10.1093/ibd/izab302] [Reference Citation Analysis]
11 James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, Sharma V. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(22)00210-9. [PMID: 35382972 DOI: 10.1016/j.dld.2022.03.005] [Reference Citation Analysis]
12 Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022;71:1426-39. [PMID: 35477864 DOI: 10.1136/gutjnl-2021-326784] [Reference Citation Analysis]
13 Li D, Xu A, Mengesha E, Elyanow R, Gittelman RM, Chapman H, Prostko JC, Frias EC, Stewart JL, Pozdnyakova V, Debbas P, Mujukian A, Horizon AA, Merin N, Joung S, Botwin GJ, Sobhani K, Figueiredo JC, Cheng S, Kaplan IM, McGovern DPB, Merchant A, Melmed GY, Braun J. The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy. Inflamm Bowel Dis 2022:izac071. [PMID: 35397000 DOI: 10.1093/ibd/izac071] [Reference Citation Analysis]
14 Czarnowska A, Tarasiuk J, Zajkowska O, Wnuk M, Marona M, Nowak K, Słowik A, Jamroz-wiśniewska A, Rejdak K, Lech B, Popiel M, Rościszewska-żukowska I, Perenc A, Bartosik-psujek H, Świderek-matysiak M, Siger M, Ciach A, Walczak A, Jurewicz A, Stasiołek M, Kania K, Dyczkowska K, Kalinowska-łyszczarz A, Galus W, Walawska-hrycek A, Krzystanek E, Chojdak-łukasiewicz J, Ubysz J, Pokryszko-dragan A, Kapica-topczewska K, Chorąży M, Bazylewicz M, Mirończuk A, Kulikowska J, Kochanowicz J, Białek M, Stolarz M, Kubicka-bączyk K, Niedziela N, Morawiec N, Adamczyk-sowa M, Podlecka-piętowska A, Nojszewska M, Zakrzewska-pniewska B, Jasińska E, Zaborski J, Milewska-jędrzejczak M, Zwiernik J, Zwiernik B, Potemkowski A, Brola W, Kułakowska A. Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. Vaccines 2022;10:763. [DOI: 10.3390/vaccines10050763] [Reference Citation Analysis]
15 Long MD, Bajaj JS. The American Journal of Gastroenterology in 2022 and Beyond: A Vision for "Our" Journal. Am J Gastroenterol 2021. [PMID: 34904963 DOI: 10.14309/ajg.0000000000001579] [Reference Citation Analysis]
16 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
17 Shehab M, Zurba Y, Al Abdulsalam A, Alfadhli A, Elouali S. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study. Vaccines (Basel) 2021;10:55. [PMID: 35062716 DOI: 10.3390/vaccines10010055] [Reference Citation Analysis]